MONTREAL, QUEBEC -- (MARKET WIRE) -- September 15, 2006 -- MethylGene Inc. (TSX: MYG), a biopharmaceutical company focused on developing products for the treatment of cancer, along with its partner Pharmion Corporation (NASDAQ: PHRM) today announced the initiation of a Phase II clinical trial with its lead histone deacetylase (HDAC) inhibitor product candidate, MGCD0103, in patients with relapsed or refractory B-cell lymphomas. Specific patient populations include patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, two tumor types that are classified as non-Hodgkin's lymphomas (NHL). The first patient was enrolled at MD Anderson Cancer Center, where Dr. Anas Younes is the principal investigator.
